Category Archives: Cancer Treatment

Home / Cancer Treatment
4 Posts

Mikhail Blagoskylonny is one of the influential oncology experts who is situated in New York City. His recognition is because of the exceptional research in cancer and aging. Most important thing is the findings that he has been able to come up with which has massively assisted in developing the oncology segment. At Rosewell Park Cancer Institute is where he always carries out his daily activity and has always worked as a professor from 2009. Furthermore, as a scientist, he has also has been included in writing and publishing cherished material that mainly emphases on cancer and aging. He is well known for motivating medical experts all over the world to use Rapamcyin in extending the lives of their patients. Mikhail also expanded the admiration in the medical rsearch sector because of the outstanding understanding of oncology.

Rapamycin has exceptional features that enable it to perform well in treating cancer and also the best drug this is according to scientific research. Furthermore, it also treats other dangerous diseases such as lymphangioleiomyomatosis (LAM), tuberous sclerosis complex (TSC) hemolytic-uremic syndrome and facial angiofibromas. The organization enabled the drug to be supplied all over the world and patients can get them easily in pharmacies. In the year 1972 is when Rapamycin was started to be used since it was revealed from a strain of bacteria that was located on Eastern Island. At first the drug was used as an anti-fungal agent but later on, the scientist became aware of the features of Rapamcyian as an immunosuppressive and antiproliferative.Due to the establishment of cancer therapies he has been known to make major innovation hence he is well recognized all over the world. Also, he led the unparalleled studies on specific cancer and anti-aging treatment. He is also certain that cancer is connected with aging because it typically affects people who have reached a particular age.

Most of the young people always see him as their role model due to the achievement in the oncology segment. Blagosklonny’s journey career has been thriving due to the amazing academic qualification. His education background is outstanding. He went to First Pavlov State Medical University of St. Peterburg and attained his Ph.D. Also, he got his master’s degree in internal medicine from the establishment as well. New York Medical College is where he started working as researcher in the year 2002, then he, later on, moved to Ordway Research Institute due to the knowledge that he attained hence he served at the organization as the senior researcher and then in the year 2009 he decides to live the organization and join Roswell Park Cancer Institute.His main daily activity at the organization was too always help in the innovation of differently targeted cancer cure. Apart from that he also studied on the specialization of aging mechanism and anti-aging drug growth. A modern research project that he is currently doing is being attentive on learning how aging and cancer are affected by the TOR signal. Lastly, also is part of the editor in the research fields that include cancer biology and therapy.

Oncotarget is the name of a medical journal that comes out on a weekly basis. The journal, as its name suggests, discusses many topics that pertain to the world of oncology. The publication was launched back in 2010. Impact Journals publishes it. Andrei V. Gudkov and Mikhail Blagosklonny both serve as Oncotarget’s editors-in-chief. IntegraGen is a company that focuses on a wide ranges of specialties. It concentrates on turning biological sample data into invaluable genomic details that can aid the field of oncology. The firm has just recently revealed the existence of an Oncotarget publication that delves into the relationship between metastatic colorectal cancer and miR-31-3p expression amounts.Oncotarget is a journal that takes a multidisciplinary approach. It’s a free access publication that has a large and devoted following.

People can read Oncotarget publications via the Internet. It can make a helpful resource for people who want to learn about all matters that relate to advancements and innovations in the oncology realm. It can also make a wonderful resource for people who want to learn more about topics such as chromosomes, cell death, autophagy, microbiology, immunology, pathology, aging and more. People who have interest in cancer and in hereditary factors frequently gravitate to the diverse publications that are available through Oncotarget each and every week.Gudkov is an editor-in-chief who works for Buffalo, New York’s Roswell Park Cancer Institute. Oncotarget’s other editor-in-chief works for the same educational institution. This is Blagosklonny. Gudkov and Blagosklonny have the assistance of a hard-working editorial board. The talented people who make up this board are Brian J. Duker, Ronald A. DePinho, Frederick Alt, Peter K. Vogt, Bert Vogelstein, Alexander Varshavsky, Gregg L. Semenza, Arthur B. Pardee, Carlo M. Croce and Arnold Levine. These capable professionals all represent a vast range of entities.

They work for institutions of higher learning such as Harvard University, Ohio State University and the Scripps Research Institute. These institutions are based in many locations all around the United States. Oncotarget is a renowned publication that always aims to keep up with changes in the oncology universe. It’s also one that constantly strives to stay ahead of the rest of the pack in the online world. Oncotarget has a great and reliable presence in social media. The publication has active presences on many widely known and beloved social networking websites. Examples of these social media platforms are Facebook, LinkedIn, Google Plus, YouTube and Twitter. People who wish to get in contact with the team members who work for Oncotarget can easily do so through channels such as Facebook and Twitter. The Oncotarget staff makes a point to get back to people quickly. They make a point to answer oncology questions in considerable detail as well. Oncotarget has approaching 1,800 followers on Twitter. The publication posts regular short messages that keep these people in the loop. These messages talk about publication frequency. They talk about changes in editorial standards and guidelines. They talk about all matters that involve how the journal works.

Oncotarget publishes the findings of numerous scientific studies on oncology and other medical-related areas weekly. It is a peer-reviewed publication. Its parent journal is Impact Journals. The Oncotarget published its premiere article approximately seven years ago. This journal has since gone ahead to publish literally thousands of other peer-reviewed and reportedly insightful articles. The articles published therein are all in English, which means that a very large part of the world’s population can read them. Officially, Oncotarget is slotted in under open-access journals. In other words, any individual interested in scientific research has a good chance of using the journal.

The Oncotarget Team

The Oncotarget team is said by online sources to be dedicated, qualified and talented. Their research record is noted to be impressive as well. Headed by chief editors professor Mikhail Blagoskloklonny and professor Andre V. Gudkov, the group makes certain that all the articles published in their publication are informational and meet high quality standards.

The chief editors are well-known, reputable professors at the Roswell Park Cancer Institute located in Buffalo, New York. Gudkov has made a major contribution to the study of numerous cancer therapies, especially concerning molecular targets and drug discovery. Blagosklonny alone has written over 250 articles in various peer-reviewed journals.

Oncotarget’s Impact Factor

During the journal’s first year in print, Oncotarget garnered an IF (impact factor) of 4.78 and was read by people in 493 cities. (That’s noteworthy for a new publication.) The following year, it was received in 1450 cities, and its IF was up to 6.636.

In 2013 Oncotarget officially registered the “highest impact factor” of 6.727. More than 2,200 cities were receiving the journal that year. The next year Oncotatget had an IF that dropped to 6.359 but this was still actually a high and consistent figure. More importantly, it was also reaching approximately 4,000 cities. More recently the journal had a steady IF of 5.168 and was being received in over 30,000 cities. The bottom line is that Oncotarget’s reception has actually multiplied by close to 100 times over the seven years it has been in existence.

To know more click here


Cancer has long been the single most dangerous affliction facing humanity at large. Those that are fortunate enough to survive their battle against cancer still suffer the debilitating symptoms brought upon by the disease itself and the very treatments designed to combat it. Though devastating, cancer is completely an issue that can be solved with the right tools and resources available to the right doctors and specialist.

The doctors of Chicago’s University of Chicago gained such a tool in their fight to better treat those in their care. Tempus, the creation of Groupon founder Eric Lefkofsky, has partnered with the medical establishment and has provided the oncology departments with access to their state of the art data collection and analyzation programs. Tempus will aid doctors by collecting and analyzing data collected from thousands of breast cancer patients to help researchers and doctors find any similarities between the data that can be used to improve treatments.The disease as dangerous as it is, has very little collected data on the patients that battle the disease.

Dr. Olufunmilayo Olopade, Dean for Global Health at the University of Chicago spoke about the lack of usable data in a statement made to press, “This forces too many physicians to make treatment decisions without the benefit of highly specific genetic information that could help them make better informed and precisely targeted decisions.” She continued, “We are excited to partner with Tempus on this initiative and eager to support its efforts to build the largest clinically annotated molecular data set in breast cancer.”The partnership comes on the heels of a string of new partnerships between the tech start-up and other establishments who are embroiled in the fight to end cancer. The start-up that sprung into the scene earlier last year has quickly gone from unknown start-up to leading the charge among tech start-ups in the fight to end cancer.